Ascendis Pharma A/S (ASND) Stock Competitors & Peer Comparison

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ASND is priced at $268.57, while VRTX trades at $477.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas VRTX's P/E ratio is 25.35. In terms of profitability, ASND's ROE is -56.42%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ASND is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check VRTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ASND is priced at $268.57, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ASND's ROE is -56.42%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ASND is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check VRNA's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, REGN has a market cap of 68.5B. Regarding current trading prices, ASND is priced at $268.57, while REGN trades at $664.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas REGN's P/E ratio is 14.56. In terms of profitability, ASND's ROE is -56.42%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ASND is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check REGN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ARGX has a market cap of 54B. Regarding current trading prices, ASND is priced at $268.57, while ARGX trades at $862.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ARGX's P/E ratio is 77.88. In terms of profitability, ASND's ROE is -56.42%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ASND is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ARGX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ASND is priced at $268.57, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ASND's ROE is -56.42%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ASND is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check SGEN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RVMDW has a market cap of 39.7B. Regarding current trading prices, ASND is priced at $268.57, while RVMDW trades at $9.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RVMDW's P/E ratio is -2.19. In terms of profitability, ASND's ROE is -56.42%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ASND is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check RVMDW's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RVMD has a market cap of 39.2B. Regarding current trading prices, ASND is priced at $268.57, while RVMD trades at $184.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RVMD's P/E ratio is -26.09. In terms of profitability, ASND's ROE is -56.42%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ASND is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check RVMD's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ALNY has a market cap of 37.3B. Regarding current trading prices, ASND is priced at $268.57, while ALNY trades at $279.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ALNY's P/E ratio is 50.30. In terms of profitability, ASND's ROE is -56.42%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ASND is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ALNY's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ONC has a market cap of 33.3B. Regarding current trading prices, ASND is priced at $268.57, while ONC trades at $311.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ONC's P/E ratio is 69.63. In terms of profitability, ASND's ROE is -56.42%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ASND is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ONC's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MRNA has a market cap of 27.1B. Regarding current trading prices, ASND is priced at $268.57, while MRNA trades at $68.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MRNA's P/E ratio is -8.38. In terms of profitability, ASND's ROE is -56.42%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ASND is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check MRNA's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, ASND is priced at $268.57, while ROIV trades at $34.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ROIV's P/E ratio is -35.86. In terms of profitability, ASND's ROE is -56.42%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ASND is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ROIV's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, INSM has a market cap of 23.8B. Regarding current trading prices, ASND is priced at $268.57, while INSM trades at $109.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas INSM's P/E ratio is -19.10. In terms of profitability, ASND's ROE is -56.42%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ASND is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check INSM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, ASND is priced at $268.57, while BNTX trades at $91.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BNTX's P/E ratio is -19.91. In terms of profitability, ASND's ROE is -56.42%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ASND is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check BNTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, INCY has a market cap of 23B. Regarding current trading prices, ASND is priced at $268.57, while INCY trades at $115.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas INCY's P/E ratio is 15.47. In terms of profitability, ASND's ROE is -56.42%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ASND is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check INCY's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, UTHR has a market cap of 22.6B. Regarding current trading prices, ASND is priced at $268.57, while UTHR trades at $531.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas UTHR's P/E ratio is 19.63. In terms of profitability, ASND's ROE is -56.42%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ASND is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check UTHR's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ASND is priced at $268.57, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ASND's ROE is -56.42%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ASND is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check BGNE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ASND is priced at $268.57, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ASND's ROE is -56.42%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ASND is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check DNA-WT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, GMAB has a market cap of 17.9B. Regarding current trading prices, ASND is priced at $268.57, while GMAB trades at $29.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas GMAB's P/E ratio is 20.92. In terms of profitability, ASND's ROE is -56.42%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ASND is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check GMAB's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, NBIX has a market cap of 17.3B. Regarding current trading prices, ASND is priced at $268.57, while NBIX trades at $171.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas NBIX's P/E ratio is 24.84. In terms of profitability, ASND's ROE is -56.42%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ASND is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check NBIX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BBIO has a market cap of 16.2B. Regarding current trading prices, ASND is priced at $268.57, while BBIO trades at $82.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BBIO's P/E ratio is -22.10. In terms of profitability, ASND's ROE is -56.42%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ASND is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check BBIO's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, ASND is priced at $268.57, while JAZZ trades at $239.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas JAZZ's P/E ratio is 18.61. In terms of profitability, ASND's ROE is -56.42%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ASND is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check JAZZ's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, ASND is priced at $268.57, while EXEL trades at $55.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas EXEL's P/E ratio is 16.63. In terms of profitability, ASND's ROE is -56.42%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ASND is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check EXEL's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, ASND is priced at $268.57, while MDGL trades at $550.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MDGL's P/E ratio is -42.99. In terms of profitability, ASND's ROE is -56.42%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ASND is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check MDGL's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ASND is priced at $268.57, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ASND's ROE is -56.42%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ASND is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check KRTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, AXSM has a market cap of 12.2B. Regarding current trading prices, ASND is priced at $268.57, while AXSM trades at $237.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas AXSM's P/E ratio is -62.02. In terms of profitability, ASND's ROE is -56.42%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ASND is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check AXSM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, ASND is priced at $268.57, while SMMT trades at $15.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas SMMT's P/E ratio is -9.42. In terms of profitability, ASND's ROE is -56.42%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ASND is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check SMMT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, ASND is priced at $268.57, while BMRN trades at $58.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BMRN's P/E ratio is 28.34. In terms of profitability, ASND's ROE is -56.42%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ASND is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check BMRN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ASND is priced at $268.57, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ASND's ROE is -56.42%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ASND is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check RNAM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ASND is priced at $268.57, while TECH trades at $71.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TECH's P/E ratio is 36.85. In terms of profitability, ASND's ROE is -56.42%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ASND is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check TECH's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, ASND is priced at $268.57, while KRYS trades at $350.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas KRYS's P/E ratio is 46.82. In terms of profitability, ASND's ROE is -56.42%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ASND is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check KRYS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CYTK has a market cap of 10.3B. Regarding current trading prices, ASND is priced at $268.57, while CYTK trades at $82.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CYTK's P/E ratio is -14.17. In terms of profitability, ASND's ROE is -56.42%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ASND is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CYTK's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, ASND is priced at $268.57, while ARWR trades at $71.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ARWR's P/E ratio is -33.40. In terms of profitability, ASND's ROE is -56.42%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ASND is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ARWR's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ABVX has a market cap of 10.1B. Regarding current trading prices, ASND is priced at $268.57, while ABVX trades at $136.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ABVX's P/E ratio is -71.78. In terms of profitability, ASND's ROE is -56.42%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ASND is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ABVX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CORT has a market cap of 9.6B. Regarding current trading prices, ASND is priced at $268.57, while CORT trades at $89.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CORT's P/E ratio is 255.91. In terms of profitability, ASND's ROE is -56.42%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ASND is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check CORT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ASND is priced at $268.57, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ASND's ROE is -56.42%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ASND is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check RXDX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, ASND is priced at $268.57, while KYMR trades at $114.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas KYMR's P/E ratio is -32.33. In terms of profitability, ASND's ROE is -56.42%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ASND is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check KYMR's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ASND is priced at $268.57, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ASND's ROE is -56.42%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ASND is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check NUVL's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, ASND is priced at $268.57, while IONS trades at $54.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas IONS's P/E ratio is -31.82. In terms of profitability, ASND's ROE is -56.42%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ASND is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check IONS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, HALO has a market cap of 9B. Regarding current trading prices, ASND is priced at $268.57, while HALO trades at $75.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas HALO's P/E ratio is 16.41. In terms of profitability, ASND's ROE is -56.42%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ASND is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check HALO's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ASND is priced at $268.57, while CRNX trades at $83.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ASND's ROE is -56.42%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ASND is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CRNX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ASND is priced at $268.57, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ASND's ROE is -56.42%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ASND is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check IMGN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, ASND is priced at $268.57, while PTGX trades at $135.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas PTGX's P/E ratio is -74.84. In terms of profitability, ASND's ROE is -56.42%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ASND is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check PTGX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ALKS has a market cap of 8.7B. Regarding current trading prices, ASND is priced at $268.57, while ALKS trades at $51.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ALKS's P/E ratio is 54.72. In terms of profitability, ASND's ROE is -56.42%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ASND is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ALKS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, ASND is priced at $268.57, while TGTX trades at $56.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TGTX's P/E ratio is 19.38. In terms of profitability, ASND's ROE is -56.42%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ASND is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check TGTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ASND is priced at $268.57, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ASND's ROE is -56.42%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ASND is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check BPMC's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ASND is priced at $268.57, while APGE trades at $134.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas APGE's P/E ratio is -31.01. In terms of profitability, ASND's ROE is -56.42%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ASND is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check APGE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, ASND is priced at $268.57, while PCVX trades at $56.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas PCVX's P/E ratio is -8.25. In terms of profitability, ASND's ROE is -56.42%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ASND is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check PCVX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ASND is priced at $268.57, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, ASND's ROE is -56.42%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ASND is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CERE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, ASND is priced at $268.57, while IMVT trades at $39.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas IMVT's P/E ratio is -14.94. In terms of profitability, ASND's ROE is -56.42%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ASND is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check IMVT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, ASND is priced at $268.57, while IBRX trades at $7.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas IBRX's P/E ratio is -9.09. In terms of profitability, ASND's ROE is -56.42%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ASND is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check IBRX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, ASND is priced at $268.57, while RYTM trades at $109.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RYTM's P/E ratio is -35.04. In terms of profitability, ASND's ROE is -56.42%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ASND is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check RYTM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ASND is priced at $268.57, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ASND's ROE is -56.42%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ASND is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check MTSR's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, LQDA has a market cap of 6.9B. Regarding current trading prices, ASND is priced at $268.57, while LQDA trades at $77.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas LQDA's P/E ratio is 555.36. In terms of profitability, ASND's ROE is -56.42%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ASND is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check LQDA's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ASND is priced at $268.57, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ASND's ROE is -56.42%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ASND is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check MRUS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ASND is priced at $268.57, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ASND's ROE is -56.42%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ASND is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ACLX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, ASND is priced at $268.57, while PRAX trades at $318.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas PRAX's P/E ratio is -23.82. In terms of profitability, ASND's ROE is -56.42%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ASND is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check PRAX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ASND is priced at $268.57, while COGT trades at $39.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas COGT's P/E ratio is -18.63. In terms of profitability, ASND's ROE is -56.42%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ASND is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check COGT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, ASND is priced at $268.57, while ERAS trades at $21.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ERAS's P/E ratio is -48.32. In terms of profitability, ASND's ROE is -56.42%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ASND is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ERAS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ASND is priced at $268.57, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, ASND's ROE is -56.42%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ASND is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check RETA's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, ASND is priced at $268.57, while PTCT trades at $78.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas PTCT's P/E ratio is -33.84. In terms of profitability, ASND's ROE is -56.42%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ASND is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check PTCT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, SRRK has a market cap of 6.5B. Regarding current trading prices, ASND is priced at $268.57, while SRRK trades at $54.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas SRRK's P/E ratio is -15.05. In terms of profitability, ASND's ROE is -56.42%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ASND is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check SRRK's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, ASND is priced at $268.57, while CGON trades at $73.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CGON's P/E ratio is -31.33. In terms of profitability, ASND's ROE is -56.42%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ASND is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check CGON's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ASND is priced at $268.57, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ASND's ROE is -56.42%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ASND is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CNTA's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, ASND is priced at $268.57, while SYRE trades at $102.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas SYRE's P/E ratio is -49.07. In terms of profitability, ASND's ROE is -56.42%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ASND is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check SYRE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ASND is priced at $268.57, while MIRM trades at $121.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MIRM's P/E ratio is -8.89. In terms of profitability, ASND's ROE is -56.42%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ASND is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check MIRM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, ASND is priced at $268.57, while BLTE trades at $149.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas BLTE's P/E ratio is -79.93. In terms of profitability, ASND's ROE is -56.42%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ASND is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check BLTE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, ASND is priced at $268.57, while LGND trades at $296.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas LGND's P/E ratio is 35.52. In terms of profitability, ASND's ROE is -56.42%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ASND is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check LGND's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ASND is priced at $268.57, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ASND's ROE is -56.42%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ASND is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CDTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ASND is priced at $268.57, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ASND's ROE is -56.42%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ASND is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ABCM's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ASND is priced at $268.57, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ASND's ROE is -56.42%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ASND is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ISEE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, ASND is priced at $268.57, while XENE trades at $67.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas XENE's P/E ratio is -14.41. In terms of profitability, ASND's ROE is -56.42%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ASND is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check XENE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ASND is priced at $268.57, while TVTX trades at $56.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TVTX's P/E ratio is -257.91. In terms of profitability, ASND's ROE is -56.42%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ASND is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check TVTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ASND is priced at $268.57, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas APLS's P/E ratio is 38.35. In terms of profitability, ASND's ROE is -56.42%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ASND is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check APLS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MANE has a market cap of 5.2B. Regarding current trading prices, ASND is priced at $268.57, while MANE trades at $123.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MANE's P/E ratio is -39.39. In terms of profitability, ASND's ROE is -56.42%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ASND is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check MANE's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, ASND is priced at $268.57, while DFTX trades at $45.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas DFTX's P/E ratio is N/A. In terms of profitability, ASND's ROE is -56.42%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ASND is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check DFTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ASND is priced at $268.57, while CRSP trades at $51.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CRSP's P/E ratio is -10.05. In terms of profitability, ASND's ROE is -56.42%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ASND is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check CRSP's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, ASND is priced at $268.57, while CAI trades at $17.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CAI's P/E ratio is -96.04. In terms of profitability, ASND's ROE is -56.42%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ASND is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check CAI's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ASND is priced at $268.57, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TERN's P/E ratio is -51.41. In terms of profitability, ASND's ROE is -56.42%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ASND is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check TERN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ASND is priced at $268.57, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ASND's ROE is -56.42%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ASND is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check FOLD's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ASND is priced at $268.57, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ASND's ROE is -56.42%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ASND is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check AKRO's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ASND is priced at $268.57, while CELC trades at $91.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CELC's P/E ratio is -23.46. In terms of profitability, ASND's ROE is -56.42%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ASND is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check CELC's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ASND is priced at $268.57, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ASND's ROE is -56.42%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ASND is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check ALPN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ASND is priced at $268.57, while ACAD trades at $25.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ACAD's P/E ratio is 12.71. In terms of profitability, ASND's ROE is -56.42%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ASND is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ACAD's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, ASND is priced at $268.57, while EWTX trades at $40.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas EWTX's P/E ratio is -24.60. In terms of profitability, ASND's ROE is -56.42%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ASND is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check EWTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, ASND is priced at $268.57, while VKTX trades at $37.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas VKTX's P/E ratio is -9.13. In terms of profitability, ASND's ROE is -56.42%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ASND is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check VKTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, ASND is priced at $268.57, while LEGN trades at $23.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas LEGN's P/E ratio is -33.88. In terms of profitability, ASND's ROE is -56.42%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ASND is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check LEGN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ASND is priced at $268.57, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, ASND's ROE is -56.42%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ASND is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check OPT's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, ASND is priced at $268.57, while DNTH trades at $99.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas DNTH's P/E ratio is -24.19. In terms of profitability, ASND's ROE is -56.42%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ASND is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check DNTH's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ASND is priced at $268.57, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ASND's ROE is -56.42%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ASND is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check MRTX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, ASND is priced at $268.57, while DYN trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas DYN's P/E ratio is -7.45. In terms of profitability, ASND's ROE is -56.42%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ASND is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check DYN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ASND is priced at $268.57, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ASND's ROE is -56.42%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ASND is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CPRX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, ASND is priced at $268.57, while TLX trades at $11.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TLX's P/E ratio is -613.59. In terms of profitability, ASND's ROE is -56.42%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ASND is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check TLX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, NAMSW has a market cap of 3.8B. Regarding current trading prices, ASND is priced at $268.57, while NAMSW trades at $20.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas NAMSW's P/E ratio is -11.37. In terms of profitability, ASND's ROE is -56.42%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ASND is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check NAMSW's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ASND is priced at $268.57, while ELVN trades at $53.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas ELVN's P/E ratio is -31.83. In terms of profitability, ASND's ROE is -56.42%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ASND is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check ELVN's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ASND is priced at $268.57, while TNGX trades at $30.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas TNGX's P/E ratio is -36.45. In terms of profitability, ASND's ROE is -56.42%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ASND is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check TNGX's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ASND is priced at $268.57, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ASND's ROE is -56.42%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ASND is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check RYZB's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ASND is priced at $268.57, while NAMS trades at $31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas NAMS's P/E ratio is -20.11. In terms of profitability, ASND's ROE is -56.42%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ASND is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check NAMS's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ASND is priced at $268.57, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ASND's ROE is -56.42%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ASND is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ASND.Check CBAY's competition here

ASND plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASND stands at 16.7B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ASND is priced at $268.57, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASND currently has a P/E ratio of -110.98, whereas DNLI's P/E ratio is -7.99. In terms of profitability, ASND's ROE is -56.42%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ASND is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ASND.Check DNLI's competition here